CBAY News and Press, CymaBay Therapeutics Inc. From 02/15/24

NEW YORK, NY / ACCESSWIRE / February 15, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Diamondback Energy, Inc. (NASD...

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.12% on the day to $32.17. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other ch...

2024-02-13 09:04:41 ET Summary Gilead Sciences' acquisition of CymaBay Therapeutics introduces seladelpar into its portfolio, expanding its presence in liver diseases. Seladelpar shows clinical promise for PBC, with significant improvements in key liver health markers and pruritus...

2024-02-12 15:06:51 ET More on CymaBay, Gilead, etc. Gilead Sciences: Cheap For A Reason Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript Gilead Sciences, Inc. 2023 Q4 - Results - Earnings Call Presentation Gilead to acquire CymaBay for $32.50/sh...

NEW YORK, NY / ACCESSWIRE / February 12, 2024 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Masonite Internat...

2024-02-12 08:53:47 ET Gilead Sciences ( NASDAQ: GILD ) has agreed to acquire CymaBay Therapeutics ( NASDAQ: CBAY ) for a total equity value of $4.3B.... Read the full article on Seeking Alpha For further details see: Gilead to acquire CymaBay for $32.50/...

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis PR Newswire - FDA has granted Priority Review with a target PDUFA date of August 14 - NEWARK, Calif. , Feb. 12, 2024 /PRNewswir...

-- Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review and Anticipated U.S. Approval in Third Quarter of 2024 -- -- Seladelpar Phase 3 Data Demonstrates a Best-in-Disease Profile for Second-Line PBC --...

NEWARK, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the Guggenheim Healt...

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 7.47% on the day to $16.4. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chro...